A personal view in The Lancet Healthy Longevity argues that sarcopenia should be reclassified as a disorder of the ageing motor system rather than of muscle tissue alone, given that motor neuron loss, denervation, and impaired neuromuscular transmission precede and drive the decline in strength and physical performance. The authors note that pharmacological agents increasing muscle mass have repeatedly failed to deliver proportional functional benefit, exposing the limits of a muscle-centric disease model. Reframing the condition around neural control has direct consequences for how strength loss is diagnosed, monitored, and treated in older adults.
Key Points
- Motor neuron and neuromuscular decline precede measurable muscle loss
- Muscle mass drugs produced inconsistent gains in real function
- Consensus criteria already prioritise strength and performance over mass
Longevity Analysis
Strength in later life depends on the integrity of the signal reaching the muscle, not merely on tissue volume, which explains why interventions aimed at mass alone fail to restore function. Correctly interpreting early markers of neural drive — movement speed, power output, coordination, and fatigue patterns — identifies decline years before conventional thresholds are crossed. The practical implication favours loading strategies that recruit high-threshold motor units and sustained training that preserves neuromuscular transmission, applied consistently rather than intermittently, since the nerve–muscle interface responds to repeated demand.
Original published by The Lancet Healthy Longevity, by Lucas B R Orssatto, W David Arnold, Luigi Ferrucci, Marco V Narici, Brian C Clark.